Stock data

正瀚-創 (6534)

正瀚-創 is a TWSE-listed company in Biotech & Medical Care. Revenue for September 2026 was NT$118.29M, up 11.5% from a year earlier. EPS over the last four quarters totals NT$5.85.

Charts, drawing tools, and the P/E calculator are in the app, free to use.

Open 正瀚-創 in Insightr